

Summary statistics - quantitative results

(Groups: measurement principle)

Filter: minimal size of the groups n = 5

EQA round: AP2/20 - Antithrombotic Agents

Deadline: 18.09.2020

RoM = robust average	AV = assigned value	Dmax = acceptable percent difference
SD = standard deviation	CRV = certified reference value	LL = lower limit
CV = coefficient of variation	RV = reference value	UL = upper limit
Ntot = total number of the participants	CVE = consensus value from experts	Neva = number of evaluated participants
Nout = number of results excluded before calculation	CVP = consensus value from all participants	Nsuc = number of successful participants
	CVPG = consensus value from participants groups	Srel = success (relative)
	U _{AV} = expanded uncertainty of the assigned value (k = 2)	

Test	[unit]	Test					Comparability							
		RoM	SD	CV [%]	N _{tot}	N _{out}	AV	U _{AV}	D _{max}	LL	UL	N _{eva}	N _{suc}	S _{rel}
Set 1														
(108) Apixaban					30							30	29	97%
Samples and groups	[µg/L]													
Sample A1		207	21	10	30	CVP	207	9,4	25%	155	259	30	30	100%
(2) Chromogenous substrat		207	21	10	30	0						30		
Sample B1		406	27	6,5	30	CVP	406	12	25%	304	508	30	29	97%
(2) Chromogenous substrat		406	27	6,5	30	0						30		
Set 2														
(109) Dabigatran					33							33	30	91%
Samples and groups	[µg/L]													
Sample A2		103	16	16	33	CVP	103	6,9	25%	77,2	129	33	30	91%
(1) Coagulometer		108	16	15	25	0						25		
(2) Chromogenous substrat		91,0	13	15	8	0						8		
Sample B2		295	32	11	33	CVP	295	14	25%	221	369	33	33	100%
(1) Coagulometer		303	30	9,8	25	0						25		
(2) Chromogenous substrat		263	26	9,8	8	0						8		
Set 3														
(110) Rivaroxaban					36							36	36	100%
Samples and groups	[µg/L]													
Sample A3		95,5	12	13	36	CVP	95,5	5,1	25%	71,6	120	36	36	100%
(2) Chromogenous substrat		95,5	12	13	36	0						36		
Sample B3		283	28	9,9	36	CVP	283	11	25%	212	354	36	36	100%
(2) Chromogenous substrat		283	28	9,9	36	0						36		

st_kn_p

End of report

Printed: 24.09.2020